Involvement of microRNAs-449/FASN axis in response to trastuzumab therapy in HER2-positive breast cancer by Ana Lameirinhas, Sandra Torres-Ruiz, Iris Garrido-Cano, Cristina Hernando, María Teresa Martínez, Ana Rovira, Joan Albanell, Sandra Zazo, Federico Rojo, Begoña Bermejo, Ana Lluch, Juan Miguel Cejalvo, Eduardo Tormo, Pilar Eroles

Get full text

Biomarkers of palbociclib response in hormone receptor-positive advanced breast cancer from the PARSIFAL trial by Joan Albanell, Angelo Gámez Pozo, Carlos L. Arteaga, Meritxell Bellet, Federico Rojo, Abel González, Beatriz Bellosillo, Violeta Serra, Petra Gener, José Antonio Guerrero, Eileen Shimizu, Mario Mancino, Jose Rodríguez-Morató, Leonardo Mina, José Manuel Pérez-García, Javier Cortés, Antonio Llombart-Cussac

Get full text

Enhancing immunotherapy through PD‐L1 upregulation: the promising combination of anti‐PD‐L1 plus mTOR inhibitors by Anna Hernández‐Prat, Alejo Rodriguez‐Vida, Laura Cardona, Mengjuan Qin, Oriol Arpí‐Llucià, Luis Soria‐Jiménez, Sílvia Menendez, Fabricio Gerel Quimis, Miguel Galindo, Edurne Arriola, Marta Salido, Nuria Juanpere‐Rodero, Federico Rojo, Aura Muntasell, Joan Albanell, Ana Rovira, Joaquim Bellmunt

Get full text

Micro Immune Response On-chip (MIRO) models the tumour-stroma interface for immunotherapy testing by Alice Perucca, Andrea Gómez Llonín, Oriol Mañé Benach, Clement Hallopeau, Elisa I. Rivas, Jenniffer Linares, Marta Garrido, Anna Sallent-Aragay, Tom Golde, Julien Colombelli, Eleni Dalaka, Judith Linacero, Marina Cazorla, Teresa Galan, Jordi Pastor Viel, Xavier Badenas, Alba Recort-Bascuas, Laura Comerma, Patricia Fernandez-Nogueira, Ana Rovira, Pere Roca-Cusachs, Joan Albanell, Xavier Trepat, Alexandre Calon, Anna Labernadie

Get full text